<DOC>
	<DOC>NCT00808028</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and immunogenicity of an investigational meningococcal B rLP2086 vaccine in adolescents aged 11 to 18 years old.</brief_summary>
	<brief_title>A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis, Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male or female subjects between the ages of &gt;=11 and &lt;=18 years at the time of enrollment. Negative urine pregnancy test for all female subjects. Parent/legal guardian or subject under supervision of the parent/legal guardian must be able to complete all relevant study procedures during study participation. History of any invasive meningococcal disease. A previous anaphylactic or severe vaccineassociated adverse reaction. Any clinically significant chronic disease. A known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids. Topical, inhaled or intraarticular corticosteroids are allowed. Participation in another investigational study in the 1month (30day) period before study visit 1 and during the conduct of the study.</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>